Full-Time
Confirmed live in the last 24 hours
Develops RNAi-based therapies for diseases
$85k - $115k/yr
Senior, Expert
Fitchburg, WI, USA
All applicants must have authorization to work in the US for a company.
Arrowhead Pharmaceuticals develops medicines aimed at treating severe diseases by targeting and silencing the genes responsible for them. The company uses RNA interference (RNAi), a natural process that reduces the expression of specific genes, to achieve effective gene silencing. This method allows Arrowhead to significantly lower the activity of harmful genes, potentially stopping or reversing diseases like cystic fibrosis and hepatitis B. Unlike many competitors, Arrowhead focuses specifically on RNAi-based therapies, utilizing a wide range of RNA chemistries and efficient delivery methods. Their goal is to meet unmet medical needs by providing new treatment options for genetic disorders, supported by partnerships with larger pharmaceutical companies and a strong pipeline of drug development.
Company Size
501-1,000
Company Stage
IPO
Headquarters
Pasadena, California
Founded
2004
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Paid Vacation
Paid Sick Leave
Mr. Apel joins the company from Walgreens Boots Alliance, where he served as Global Head of Financial Planning and Analysis from 2019 through 2024.
Arrowhead Pharmaceuticals launches FCS patient resources on Rare Disease Day.
New Patient Resource Hub: Arrowhead expands its We'll Get There Soon campaign with the launch of a dedicated patient website, providing education, tools, and support for those living with FCS and extremely high triglycerides
Recently, Arrowhead Pharmaceuticals and Sarepta Therapeutics signed a global licensing and collaboration agreement to develop clinical and preclinical programmes.
Sarepta Therapeutics is putting massive biobucks on the line to work on RNA drugs with Arrowhead, paying out $500 million upfront to find new treatments for rare genetic diseases of the muscle, central nervous system and lung.